We receives advance assurance for EIS status in the United Kingdom
post-template-default,single,single-post,postid-16360,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Japanese Patent Office announces its intention

Japanese Patent Office announces its intention to grant Evolution  Biotechnologies Application No. 2018-525822, “Acaricidals”

Bedford, UK, February 1st 2021

Evolution Biotechnologies (www.evolutionbiotech.com), the UK based company pioneering the use of biological control to benefit human health, today announced that it has been notified  by the Japan Patent Office of their intention to grant Patent Application No. 2018-525822,  “Acaricidals”, deriving from WO2017025732A1 “Acaricides”, This will provide broad  protection for both formulation and use of Evolution’s biological control technology for house  dust mites in the control of asthma and other allergic diseases.

As a result of this award, Evolution will now have exclusive control of the Japanese market for  this uniquely capable and environmentally friendly technology. The Japanese market is  projected to have potential for sales of more than $300M per annum, in addition to the $600M  projected for existing protected markets in Europe and Hong Kong.

Corresponding applications are awarded in Europe and Hong Kong and are under examination  in the USA and Australia, leveraging the highly favourable PCT international examination  report (IPRP).

Dr. David Harper, Evolution’s CEO, said “this is another step forward for the company,  providing exclusivity for this uniquely capable approach in a new, large market, with high  levels of unmet need.”

According to a recent report on dust mite allergy in Japan, “As of March 2019, about 22  percent of respondents aged 30 to 39 years reported to suffer from house dust or dust mites  allergies” (https://www.statista.com/statistics/831533/japan-dust-mites-allergy-by-age group/).

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of  environmentally friendly biological control from its proven efficacy in agriculture into  biomedical markets. The company’s initial target is the development of a novel, self amplifying biological control for the house dust mite, an expanding multi-billion dollar market  with high value and significant unmet need. Asthma is a worldwide, chronic disease and house  dust mite allergens are key to both sensitization and the triggering of attacks. The number of  asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent  hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed  $100 billion in the EU and US alone.

Colworth Science Park, Sharnbrook, Bedford MK44 1LQ Registration No: 09473027 VAT No: 233307048

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly.  The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to  pose fewer risks than conventional pesticides, EPA generally requires much less data to register  a biopesticide”. Biological control methodologies have been extensively used in the  agricultural and food safety sectors and provide a “green” alternative to existing chemical  approaches, especially where there are concerns over toxicity or resistance. Despite the  validated route through the regulatory process and onto the market, application in the domestic  and medical settings has received only limited attention to date. Evolution’s work is leading  this important expansion of this proven approach into high value markets with unmet clinical  need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not  historical facts, including statements about our beliefs and expectations. These statements are  based on plans, estimates and projections at the time we make the statements. Forward-looking  statements involve inherent risks and uncertainties. A number of important factors could cause  actual results to differ materially from those contained in any forward-looking statement. 

Media contacts;

Email: pr@evolutionbiotech.com
Website: www.evolutionbiotech.com



No Comments

Sorry, the comment form is closed at this time.